Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMISE: Optimized Immunosuppression for Corneal Transplantation
NCT05716945Phase 4Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2024
- Primary completion
- Sep 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of fluorometholone in corneal graft rejection (CGR), sponsored by Maastricht University Medical Center+. Started Jul 2024; status: recruiting.
02
Drugs
fluorometholone
03
Conditions
corneal graft rejection (CGR)
Beyond the preview
Go deeper on NCT05716945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716945.